A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Propranolol (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ProSun Study
- 08 Jan 2019 Status changed to withdrawn prior to enrolment.
- 19 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
- 21 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.